Background
Tuberous sclerosis complex (TSC) is a rare autosomal dominant genetic disorder with a prevalence of 1 in 6000, caused by pathogenic variants in the
TSC1 or
TSC2 genes [
1]. TSC is characterized by benign tumor growth in various organ systems, including the skin, kidneys, lungs, heart, and brain [
2]. Epilepsy is a common feature of TSC and is often present in the first year of life (80%) [
3]. In addition, TSC is associated with varying degrees of intellectual disabilities (ID) (50%) [
4] and TSC-associated neuropsychiatric disorders (TAND) (90%) [
5], which encompass psychiatric, behavioral, intellectual, neuropsychological, academic, and psychosocial manifestations [
3,
4]. The severity of TSC manifestations can vary greatly but health perception and functioning are often severely impaired [
6‐
9].
With improved healthcare, the largest population with TSC is now adult. Thus far, little is known of the burden and restrictions experienced by adults with TSC and the impact of TSC on functioning. As there is great variability in the severity of organ-specific involvement per life phase [
2], adult care is often variable and fragmented, including gaps in care for TAND [
5,
10‐
12]. Therefore, measuring the impact of various manifestations of TSC on functioning is both important and challenging and could improve care and allow monitoring over time. Moreover, if individuals with TSC have learning difficulties and mental health problems, they may have difficulties indicating their symptoms or healthcare needs, resulting in unknown and hence unmet healthcare needs. This could, in turn, lead to impaired functioning [
10,
13,
14].
Various outcomes have been measured to assess disease severity in TSC research. Clinical or surrogate outcomes are often narrow in their focus, and it is unclear whether changes are relevant. For instance, although (severity of) epilepsy has been directly related to functioning [
6,
15], reduction of seizure frequency does not always lead to improved functioning [
16,
17]. In addition, what clinicians consider relevant is not identical to what individuals with TSC find important. The International Classification of Functioning and Disability (ICF) is a biopsychosocial model of disability based on an integration of the social and medical models of disability (World Health Organization 2001). The ICF conceptualizes a person’s level of functioning as a dynamic interaction between health conditions, environmental factors, and personal factors.
To get a better understanding of functioning and what is relevant to individuals, a patient-reported outcome measure (PROM) would allow an insight into perceived severity and impact. PROMs are questionnaires that measure how an individual experiences his or her own health [
18‐
20]. They have become important for value-based healthcare and shared-decision making [
21] and are increasingly used in practice and scientific research to quantify the severity and impact of the diseases on daily functioning from the perspective of the individual. PROMs enable periodical and quantitative evaluation of symptoms and functioning of the patient population. It can thus be used for monitoring and informing care, and as an outcome measure for trials [
22].
Questionnaires commonly used in TSC trials, such as the Pediatric Quality of Life Inventory (PedsQL™ 4.0) [
23] and Short-Form 36 (SF-36) [
24], do not include disease-specific symptoms and may not be responsive enough for individuals with TSC [
25,
26]. In addition, adults with TSC may or may not be able to self-report, and most existing questionnaires for adults are most commonly solely available as self-report. Adult proxy-report questionnaires are often unavailable for the domains of interest. It has been suggested that health problems in TSC are underestimated by excluding the more severely affected individuals, preventing them from early interventions [
27‐
29]. Previous clinical trials that did not demonstrate significant clinical benefits based on parent-reported PROMs as primary outcome measures, such as the Aberrant Behavior Checklist – Irritability subscale [
30], have been considered unsuccessful even when secondary outcome measures, such as visual analog scale ratings of parent-nominated problem behaviors or subscales validated for that specific patient population, indicated positive improvements [
31]. This raises questions about whether the intervention was truly ineffective or whether the measurement instrument or mode of administration (proxy-report) was not responsive to therapy or suitable for the population being studied.
Especially now that disease-modifying and often long-term and expensive therapies are increasingly available, there is an urgent need for a TSC-specific PROM to measure effects of clinical parameters and treatment on disease-specific functioning, in both clinical and research settings. The use of a TSC-specific PROM in clinical trials can provide valuable evidence of the risks and benefits of treatments from a patient perspective which can inform regulatory approvals, clinical guidelines, and health policy, as it captures information that is relevant to the individual with TSC [
32]. Therefore, the development of a reliable and valid instrument that measures domains and symptoms relevant to individuals with TSC is a top priority for patient organizations, researchers, and healthcare providers [
5,
33,
34].
The aim of the current study was to develop and validate a TSC-specific PROM that captures the impact of TSC on physical and mental functions, activity and participation, and social support received by individuals with TSC, using the framework of the ICF (World Health Organization, 2001). The questionnaire is called TSC-PROM and consists of separate versions in English and Dutch for self-report and proxy-report, with the latter being the most suitable option to receive information about the possibly experienced issues for individuals who are unable to report on themselves.
Discussion
The TSC-PROM is the first TSC-specific outcome measure comprehensively addressing all relevant aspects of the ICF model for adults with TSC. It is developed and validated according to the gold standard COSMIN, with versions for proxies of individuals with TSC who are unable to use it themselves (see Additional file
2 and 3). The TSC-PROM may be used in both research and clinical settings to assess physical and mental functions, activity and participation, and social support individuals with TSC receive. To date, the TSC-PROM is available in English and Dutch, but translation into other languages and an accessible digitalized version will allow broader evaluation and application of this TSC-specific PROM.
Psychometrics
Psychometric evaluation shows that the TSC-PROM has sufficient validity and reliability to serve as an instrument to systematically gain insight into the impact of TSC on physical functions, mental functions, and activity and participation and the social support individuals with TSC receive and provides a vital addition to current clinical outcomes.
The most important part of the development of the TSC-PROM is content validity [
65] which was ensured and verified by all major stakeholders, including individuals with TSC and a broad multidisciplinary team of TSC experts. Some adjustments were made based on the feedback received during the cognitive interview study in the participating countries, and feasibility, comprehensibility, relevance, and comprehensiveness were demonstrated. However, cross-cultural validity has not yet been examined, and cultural adaptations may be necessary when using the TSC-PROM in other countries and languages. Satisfactory results were demonstrated on internal consistency and structural validity. Unidimensionality was satisfied, but there was some overlap between items indicated by local dependencies. This may be explained by the fact that items were divided into clusters with overlap in content of symptoms which often co-exist. Satisfactory results were also demonstrated on construct validity, although not all hypotheses with regard to discriminative validity were met, in particular for the proxy version. These results may reflect the heterogeneity of the TSC population and indicate that function for individuals with TSC is difficult to determine by proxy-reports [
42]. Furthermore, higher scores of the TSC-PROM indicating better functioning were observed for self-ratings compared to proxy-ratings (
p < 0.001,
r = − 0.50), perhaps because the proxy-ratings concern individuals who are more affected by the neurological manifestations of TSC or due to bias of the rating as in other studies proxy-raters often seem to assess functioning as worse [
66‐
68].
Recommendations for use in the care setting
The TSC-PROM can provide quantitative evaluation of the severity and impact of TSC on various health domains and daily functioning from the patient’s perspective. As such, it might be used for monitoring and informing care. The instrument might also serve as a tool to facilitate detection of healthcare needs before or during a clinical visit. Although it is an elaborate questionnaire and it might take some time to complete, it consists of all relevant items. However, not all items or domains are always applicable to individuals with TSC due to the heterogeneity and treatment goals. Therefore, a subdomain could be used as well rather than the whole instrument, although it might still be valuable to use all domains in order to not forget about possible manifestations. It ensures an effective follow-up and timely referral to appropriate care providers. Until now, assessments of disease severity using clinical rating scales such as the clinical global impression scale omitted patient perspectives about issues of relevance to their health. Additionally, it has been pointed out that perception of the individuals’ functioning by clinicians and individuals themselves differ [
69,
70]. Using the TSC-PROM may improve communication between the individual and clinician and treatment outcomes and facilitate shared-decision making, resulting in increased satisfaction with care.
Recommendations for use in research
The TSC-PROM can bridge the gap between care and interventional research. It can be used as an outcome measure to gain insight into patients’ perspective on physical functions, mental functions, activities and participation, and the social support individuals with TSC receive, in observational, epidemiological, and longitudinal studies and in interventional trials. It can also relate therapeutic or biomarker findings to self-evaluated functioning. This is important for evaluating novel treatments such as anti-seizure medication, mTOR inhibitors, cannabidiol treatments, and eventually more (expensive) targeted therapies such as gene or RNA modification [
2,
71]. Although a TAND-specific outcome measure is under development [
72], the assessment of all relevant health domains in individuals with TSC has been hampered by the lack of a TSC-specific measure [
9], comparable to several other rare diseases for which disease-specific outcome measures have eventually been developed [
28,
73‐
76].
Thus far, generic instruments have been used with the advantage of allowing comparison between different disease (sub)groups. However, these PROMs often do not include all relevant domains of functioning in TSC or proxy versions for adults are not available [
10,
17]. As a result, multiple tools have been used in single trials to measure the full impact. As the TSC-PROM addresses all domains of the ICF framework relevant to individuals with TSC while displaying convergent validity to existing generic instruments (SF-36, ASR, CBCL), it may better capture all important manifestations and aspects that impact the functioning of individuals with TSC than existing instruments.
Strengths, limitations, and future directions
The TSC-PROM provides an innovative tool to measure what is relevant to individuals with TSC, taking into account the complexity and heterogeneity of the clinical picture of TSC. It has been developed together with individuals with TSC and according to the gold standard COSMIN, providing high relevancy and good quality. It might serve as an example for future work for heterogeneous and complex disorders where existing instruments are unavailable for proxy-report and the domains of interest.
However, limitations of this study are the sample size and representation of a limited number of countries and languages, as there will be differences between countries and cultures regarding healthcare systems. According to COSMIN criteria, a sample size between 50 and 100 per age group is regarded a good sample size for establishing internal consistency and reliability in a PROM [
34]. We aimed for a representative sample size of 200 participants, but a part of the participants did not complete the questionnaire battery. The majority of participants were from the Netherlands, although Belgium, American, Canadian, British, Spanish, and Finnish nationalities were included as well, as we recruited in the Netherlands, Belgium, and the USA without restrictions on nationality. In this study, we started to develop a Dutch and English instrument which was tested in the three participating countries. We have not yet examined the applicability for other countries, neither whether cultural adaptations are needed. Next, the TSC-PROM should be translated into other languages such that all individuals with TSC could benefit regardless of their language, country or culture, ensuring inclusivity.
Future interventional studies should evaluate responsiveness to change, test–retest validity and cross-cultural validity of the TSC-PROM and elaborate on discrepancies in functioning between self-reports and proxy-reports in which both the self and proxy versions are completed for one individual. Also, a shortened version of the TSC-PROM or more advanced psychometric methods such as item response theory (IRT-)based instruments might be developed for individuals with mild ID [
77]. Ideally, a generic measure should be developed applicable to all rare genetic neurodevelopmental disorders with appropriate versions for different levels of ID with different symptom checklists to cover relevant disease-specific aspects, as it is not feasible and desirable to have disorder-specific PROMs for all these thousands of disorders.
Conclusions
The TSC-PROM is the first TSC-specific outcome measure for adults with TSC, which has been developed using the ICF structure covering all relevant aspects of physical functions, mental functions, activities and participation, and social support and with input from individuals with TSC, caregivers, clinicians, as well as literature review and psychometric testing. It appears to have adequate to good psychometric properties of acceptability, reliability, and validity. This TSC-specific PROM provides a unique tool to systematically gain insight into the individuals’ experiences and monitor trial and therapy outcome, taking into account the complexity and heterogeneity of the clinical picture of TSC, and empowering TSC clinicians and researchers in the optimal care for adults with TSC.
Acknowledgements
We would like to acknowledge the individuals with TSC and their representatives who participated in the study and Jo Anne Nakagawa, Eva Schoeters, and Jan-Paul Wagenaar on behalf of the patient organizations from the US (TSC Alliance), Belgium (BeTSC), and the Netherlands (Stichting Tubereuze Sclerosis Nederland), respectively. We also want to thank Molly Griffith and Lauren Davis from Cincinnati Children’s Hospital Medical Center and Le Bonheur Children’s Hospital Memphis who helped with recruitment. Prof. Jan van der Ende is thanked for his methodological contribution to developing the TSC-PROM. Furthermore, we are grateful to the Dutch TSC Foundation (Stichting TSC Fonds) for financially enabling this study. AJ is supported by a Senior Clinical Investigator Fellowship from the Research Foundation Flanders (FWO FKM 1805321N). AvE, LdG, MdW, and LtH are member of European Reference Network (ERN) ITHACA. LdG is affiliated with ENDO-ERN.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.